This aerial photo shows a general view of containers at Qingdao port, in China's eastern Shandong province on June 9, 2026. (Photo by CN-STR / AFP via Getty Images) / China OUT

This aerial photo shows a tanker unloading imported crude oil at a terminal port in Qingdao, in China's eastern Shandong province on June 9, 2026. (Photo by CN-STR / AFP via Getty Images) / China OUT

This aerial photo shows a tanker unloading imported crude oil at a terminal port in Qingdao, in China's eastern Shandong province on June 9, 2026. (Photo by CN-STR / AFP via Getty Images) / China OUT

A container ship is berthed at the container terminal of Qingdao port, in China's eastern Shandong province on June 9, 2026. (Photo by CN-STR / AFP via Getty Images) / China OUT

A dealer stands near the screens showing the foreign exchange rate between U.S. dollar and South Korean won at a dealing room of Hana Bank in Seoul, South Korea, Tuesday, June 9, 2026. (AP Photo/Lee Jin-man)

People stand near the screens showing the Korea Composite Stock Price Index (KOSPI) and the foreign exchange rate between U.S. dollar and South Korean won at a dealing room of Hana Bank in Seoul, South Korea, Tuesday, June 9, 2026. (AP Photo/Lee Jin-man)

Head of the industry association HotellerieSuisse, Martin von Moos poses during the Hospitality Summit in Bern, on June 3, 2026. Swiss business leaders and unions are mobilising ahead of a vote on June 14, 2026 on capping immigration, which has triggered fears of dire impacts on employment and trade relations with the European Union. The vote will focus on a proposal by the hard-right Swiss People's Party (SVP) aimed at keeping the wealthy Alpine nation's population -- currently 9.1 million -- below 10 million until 2050. (Photo by Nathalie OLOF-ORS / AFP via Getty Images)

(FILES) This photograph taken on January 5, 2023 shows the logo of GSK pharmaceutical laboratory in Mayenne, western France. The British pharmaceutical giant GSK announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by JEAN-FRANCOIS MONIER / AFP via Getty Images)